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ABSTRACT
Objective: Hematopoietic stem cell transplantation is an
accepted treatment of hematological malignancies, but the
cost-effectiveness of this technology has not been fully
explored. This study aims to assess the cost-effectiveness of
stem cell transplantation from either cord blood or bone
marrow/peripheral blood compared with no transplantation
in adult patients with acute leukemias not expected to be
cured with chemotherapy.
Methods: A systematic review was performed to estimate the
efﬁcacy of unrelated cord blood and bone marrow/peripheral
blood stem cells (BM/PBSC) transplantations in adults with
acute leukemia. A Markov decision analysis model using
Monte Carlo simulations was used to calculate the incremen-
tal cost-effectiveness ratio (ICER) and 95% conﬁdence inter-
vals (CIs).
Results: The estimated cumulative survival at 1 and 10 years
were 27.9% and 14%, respectively, for cord blood recipients
and 47% and 17.7%, respectively, for BM/PBSC recipients.
Using conservative assumptions, the cost per life-year gained
compared with no transplantation was US $16,346 (95% CI
$8695, $38,006) for BM/PBSC transplantation and US
$34,360 (95% CI $23,101, $89,417) for cord blood
transplantation.
Conclusions: Although both types of stem cell transplanta-
tions are associated with a high short-term mortality and
high cost, the cumulative gains in life-years of survivors can
be substantial, resulting in ICERs compared with no trans-
plantation that are usually considered acceptable. However
there is less certainty about this conclusion with cord blood
transplantation.
Keywords: bone marrow stem cells, cord blood, cost-
effectiveness, mortality, peripheral blood stem cells, stem cell
transplantation.
Introduction
Hematopoietic stem cell transplantation (HSCT) with
its ability for pluripotential differentiation is an estab-
lished clinical procedure to treat hematological malig-
nancies [1]. The stem cells may be obtained from the
patient’s own bone marrow (autologous transplanta-
tion), a suitably matched related donor (related allo-
geneic transplantation) or from an unrelated donor
(unrelated allogeneic transplantation) [2]. Allogeneic
stem cell transplantation is indicated for acute and
chronic leukemias, myelodysplastic syndrome, and
severe aplastic anemia among other conditions [3].
Strict human-leukocyte antigen (HLA) matching for
allogeneic bone marrow/peripheral blood stem cells
(BM/PBSC) transplantation is necessary to minimize
rejection and severe graft-versus-host disease (GVHD),
which can affect both quality of life and survival
[2,4,5]. Unfortunately, for approximately two-thirds
of the patients a suitable matched sibling donor cannot
be found, and in less than 50% of these patients can a
suitable matched unrelated donor be found [2,4].
BM/PBSC transplantation from unrelated donors may
be associated with worse outcomes compared with
sibling donors because of increased HLA disparity
[4,5].
Umbilical cord blood is an alternative source of
pluripotential hematopoietic stem cells that has the
potential of signiﬁcantly reducing this unmet medical
need [5]. As cord blood T lymphocytes are more naive
than those derived from BM/PBSC, there is a lower
chance of rejection and GVHD, which allows for less
strict HLA-matching requirements, thereby increasing
matching possibilities [6]. Another advantage of cord
blood is a lower risk of transmission of viral diseases
[6]. Limitations include a higher cost, slower hemato-
logical recovery, and sometimes less successful engraft-
ment [7], especially in larger adults [6]. Cord blood
stem cell transplantation from unrelated donors began
in 1993 [6] and has now reached 4000 to 6000 trans-
plantations annually [8].
Brieﬂy, patients with hematological malignancies
ﬁrst undergo immunosuppression via chemotherapy
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and/or radiotherapy [6] to avoid rejection of the stem
cells and to eradicate residual malignant cells [9]. After
such conditioning treatment, the frozen stem cells are
thawed at the bedside [10], and infused intravenously
over a few minutes. The recovery of the patient’s
immune system depends on the engraftment and pro-
liferation of the infused stem cells [10].
Despite the clinical advances with stem cell trans-
plantation, few studies have addressed the issue of
cost. Therefore, the purpose of the present study is to
examine the cost-effectiveness of unrelated cord blood
or BM/PBSC transplantation compared with no trans-
plantation in adult patients with acute leukemia who
are not expected to be cured with further courses of
chemotherapy/radiotherapy.
Materials and Methods
Systematic Review
Our base-case study population is adult patients with
acute leukemia in remission, but that are not expected
to be cured with further courses of chemotherapy/
radiotherapy, and who lack a related donor and are
therefore considered eligible in our institution for
unrelated HSCT. Typically, patients are <50 years with
a score of 3 or better in the Eastern Cooperative
Oncology Group (ECOG) performance status (ECOG
3 = Capable of only limited self-care, conﬁned to bed
or chair more than 50% of waking hours) [11]. Our
institution performs approximately 50 to 55 stem cell
transplantations annually.
In order to obtain an unbiased measure of efﬁcacy,
a systematic literature review using the terms “stem
cell,” “cord or umbilical or bone marrow or peripheral
blood,” “transplantation,” and “unrelated” was per-
formed to identify previous studies of stem cell trans-
plantation from unrelated donors in adult patients
with acute leukemias. The search was performed using
the PubMed, EMBASE, and International Network of
Agencies for Health Technology Assessment databases,
the Cochrane Database of Systematic Reviews, and
references from the identiﬁed studies. Web sites of
professional associations in the ﬁeld such as the
National Marrow Donors Program (NMDP), the
International Bone Marrow Transplant Registry were
also searched in an attempt to identify the most
studies. Only articles in English or French and pub-
lished after January 2000 were reviewed (last search
on December 7, 2005). Study inclusion criteria
included: 1) a sample size of at least 30 adult patients
receiving allogeneic transplantation from unrelated
donors; 2) reporting of overall mortality; and 3) at
least 50% of patients with acute leukemia. Studies that
considered adult and pediatric patients jointly or
studies with reduced-intensity pretransplantation con-
ditioning regimens were excluded.
Because only observational studies were located, we
followed the MOOSE (Meta-analysis of Observational
Studies in Epidemiology) criteria [12] in performing
this systematic review. The clinical endpoints extracted
from this systematic review included survival at differ-
ent time intervals and complications rates. We have
focused on patients with acute leukemia and excluded
those with less advanced disease as this approximates
our base-case population.
Decision Analytic Model
Among the transplanted patients, ﬁve health states
were permitted: survival, death, and alive with chronic
GVHD, disease relapse, or infection. Patients without
transplantation have a very limited life expectancy
[13–19] and therefore only two states are assigned to
this group: survival and death. The model is shown in
Figure 1.
The incremental cost-effectiveness ratios (ICERs),
of unrelated allogeneic cord blood and BM/PBSC
transplantations, compared with no transplantation
were calculated using a Markov decision model
(TreeAge Pro 2006 Suite, TreeAge Software Inc., Wil-
liamstown, MA, USA). The model allowed for 20
1-year cycles. During each cycle, patients may survive
with or without complications or die. As outcomes are
assigned at the end of each cycle, patients who died in
a given year were also at risk of experiencing a com-
plication during that cycle. Patients may experience
more than one complication during each cycle and
they may return to a different state in the next cycle.
The only absorbing state in our model is “not survive”
and half-cycle correction was employed. Separate
models compared each source of stem cells with no
transplantation. We did not compare cord blood trans-
plantation directly with BM/PBSC transplantation.
Transition probabilities for survival and other
health states after transplantation were derived from
the systematic review. A weighted average of these
results was calculated using the inverse variance
method.
Annual survival rates were calculated through inter-
polation. We assumed that the cumulative rate of
chronic GVHD and disease relapses reported in the
studies identiﬁed occurred in Year 1 unless otherwise
speciﬁed. Because long-term studies of related and
unrelated allogeneic bone marrow transplantation
have shown that the mortality curves reach a plateau
between Years 5 and 10 post transplantation [20–23],
we did not attribute any additional disease or proce-
dure mortality after 5 years. Long-term survival was
assumed to follow that of the Quebec general popula-
tion [24]. Although after the 10th year the limited
information indicates that most patients may be con-
sidered “cured” [25], given the paucity of long-term
data, we assumed an average survival of only 50% the
population estimate. The average life expectancy of a
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58-year-old survivor, according to the Quebec popula-
tion life-expectancy tables, is approximately 20 (male)
to 25 (female) years [24]. Therefore, we have conser-
vatively assumed an average survival for these indi-
viduals of only 10 additional years (20 years total since
transplantation).
Costs
Costs were calculated according to a single provincial
payer perspective and included the direct medical costs
of hospitalization, inpatient and outpatient medica-
tions, nursing and physicians’ costs. Hospitalization
costs, excluding ﬁxed overhead costs, for all allogeneic
cord blood and PBSC transplantations in 2004 were
estimated based on ﬁgures supplied by our ﬁnance
department. Costs between hospital discharge and Day
100 were derived from a previous Canadian BM/PBSC
transplantation study [26] and included early trans-
plantation failures such as nonengraftment and acute
GVHD (adjusted for inﬂation). Later costs were calcu-
lated by multiplying literature-reported complication
rates by their estimated costs. Since those surviving
beyond 10 years may be considered “cured” [25], no
additional treatments costs were considered. In the
nontransplantation group, costs consist of chemo-
therapy and palliative care. Costs are reported in 2004
US dollars and a baseline discounting rate of 3% was
applied for both costs and outcomes.
Sensitivity Analyses
The robustness of our assumptions was tested by
univariate and multivariate sensitivity analyses. In
univariate sensitivity analyses, we considered a 250%
increase in costs to approximately scale our costs to
the American context. Other univariate sensitivity
analyses truncated survival at 10 years, as this is the
limit of the reported literature experience, and varied
nontransplantation group survival to 3 years without
assuming additional costs. These sensitivity analyses
were biased against the two transplantation technolo-
gies and therefore our results represent conservative
cost-effectiveness estimates. Robustness to varying dis-
count rates was also examined.
Multivariate probabilistic sensitivity analyses on
both survival and cost variables were performed using
1000 Monte Carlo simulations [27,28] to estimate the
95% conﬁdence interval for the ICER [29]. Survival,
complication rates, and costs were simultaneously
varied using the beta distributions for rates and trian-
gular distributions for cost variables.
Results
Clinical Outcomes
No randomized trials of HSCT efﬁcacy were identiﬁed.
Seven cord blood [30–36] and four BM/PBSC trans-
plantation [34,35,37,38] observational studies, and
the NMDP [20] registry met our inclusion criteria (see
Table 1). By excluding NMDP patients in ﬁrst com-
plete remission (CR1), we have selected those with
more advanced disease and more representative of our
population. A systematic review of cord blood trans-
plantations was identiﬁed [39], but it did not meet our
inclusion criteria. Overall, the retained published
Figure 1 Simpliﬁed Markov decision model used to calculate the incremental cost-effectiveness ratio for cord blood and bone marrow/peripheral blood
stem cells transplantation compared with no transplantation. HSCT, hematopoietic stem cell transplantation. Each complication was modeled separately.
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studies included 906 cord blood and 3150 BM/PBSC
transplantation patients.
Studies provided survival information up to 5 years
post transplantation (Table 2) with uniformly high
early post-transplantation mortality. The weighted
average clinical outcomes were then used to populate
the Markov decision model. The 10-year survival was
estimated at 17.7% for BM/PBSC and 14% for cord
blood.
Base-case patients (adults with acute leukemia not
expected to be cured with chemotherapy/radiotherapy
and who lack a related donor) who do not receive a
transplantation have a very limited survival. The esti-
mated life expectancy for these patients at our institu-
tion is approximately 9 months, which is slightly
higher than the 2–6 months reported in the literature
[13–19], resulting in a conservative ICER of stem cell
transplantation.
Economic Analysis
Clinical and economic parameters for our model are
shown in Tables 3 and 4. Transplantation, ﬁrst-year
and total 10-year cumulative costs were estimated at
$80,407, $92,330, and $92,859, respectively, for cord
blood transplantations, and $56,563, $69,830, and
$70,395, respectively, for BM/PBSC transplantations
(3% discounting), with most costs occurring early. The
estimated cost in patients without transplantation is
$20,702 assuming that they would undergo four cycles
of chemotherapy and 1 month of palliative care in
hospital.
The estimated ICERs for cord blood and BM/PBSC
were $34,360 and $16,346, respectively (Table 5). In a
univariate sensitivity analysis, increasing the treatment
costs by 250% yielded an ICER of $56,235 for cord
blood, and $30,113 for BM/PBSC. Using a truncated
10-year survival resulted in an ICER of $61,673 for
cord blood and $26,717 for BM/PBSC. Although a
10-year time frame relies less on data extrapolations,
this could lead to an underestimation of the cost-
effectiveness.
Figure 2 illustrates the univariate sensitivity analy-
ses obtained by varying the survival in the nontrans-
plantation group without considering the potential
additional costs incurred. For BM/PBSC, the ICER
remained relatively stable, but cord blood transplanta-
tion eventually becomes dominated by nontransplan-
tation with an improved 3-year survival (2.91 vs.
2.85 years) with lower costs ($20,702 vs. $92,859).
Varying the discount rate from zero to 6% in univari-
ate sensitivity analyses resulted in ICERs ranging from
$26,207 to $43,751 for cord blood, and $12,855 to
$20,176 for BM/PBSC transplantation compared with
no transplantation.
Table 1 Characteristics of the studies included in the analyses
Studies
N (N1)
Median
follow-up
(years)
Age (years)
Median (range) HLA mismatches Underlying disease
BM/PBSC transplantations
Rocha et al. [34]
N = 584 (584)
2 32 (15–59) None: 584 (100%) >CR1: 387 (66%)
Laughlin et al. [35]
N = 450 (241)
4 >40 years: 139 (38%)
>40 years: 24 (29%)
None: 367 (100%)
1: 83 (100%)
>CR1, CP1 or RA or
relapse: 274 (61%)
Nivison-Smith et al.
[38] N = 57 (57)
5 Adults NR >CR1: 57 (100%)
Fauser et al. [37]
N = 74 (36)
1.5 36 (18–56) None: 74 (100%) High risk: 34 (46%)
National Marrow
Donors Program
statistics [20]
N = 1985 (1985)
5 NR NR >CR1: 1985 (100%)
>CR3 or relapse:
1343 (68%)
Cord blood transplantations
Laughlin et al. [30]
N = 68 (34)
1.8 31.4 (18–58) None: 2 (3%)
1–2: 55 (81%)
NR
Gluckman et al. [31]
N = 108 (55)
1.7 Mean: 26 (15–53) None: 6 (5.6%)
1: 102 (94.4%)
NR
Long et al. [32]
N = 57 (34)
NA 31 (18–58) None: 2 (4%)
1–2: 52 (91%)
(91% of leukemias >
CR1)
Stevens et al. [33]
N = 391
5 >40: 125 (32%) NR Advanced leukemia:
41%
Rocha et al. [34]
N = 98 (98)
2.3 24.5 (15–55) None: 6 (6%)
1–2: 85 (87%)
>CR1: 72 (73%)
Laughlin et al. [35]
N = 150 (103)
3.3 >40: 26% 1–2: 150 (100%) Patients in >CR1, CP1
or RA or relapse: 120
(80%)
Cornetta et al. [36]
N = 34 (28)
NA 34.5 (18–55) None: 1 (3%)
1–2: 33 (97%)
Poor risk: 32 (94%)
(NMDP criteria)
Leukemia includes acute lymphoblastic leukemia and acute myeloid leukemia.
BM/PBSC,bone marrow/peripheral blood stem cells;CP, chronic phase;CR, complete remission;HLA,human-leukocyte antigen;N, total number of patients;N1, number of patients
with acute leukemia; NR, not reported; RA, refractory anemia.
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Table 2 Survival rates in adult patients undergoing stem cell transplantations from unrelated donors for leukemia
Survival 100 days 1 year 3 years 5 years
BM/PBSC transplantations
Rocha et al. [34] N = 584 NR 50%* NR NR
Laughlin et al. [35] (matched)
N = 367
66% 45%* 35% 33%*
Laughlin et al. [35] (mismatched)
N = 83
45% 30%* 20% 20%*
Nivison-Smith et al. [38]
N = 57
NR NR NR 28.9% (acute
leukemia > CR1)
Fauser et al. [37] N = 74 NR 55.4%* NR NR
NMDP statistics [20]†
N = 1985
NR NR NR 16.2% (acute
leukemia > CR1)
Weighted average (SD) 62.4% (5.4%) 47.0% (5.7%) 31.3% (4.4%) 18.2% (4.4%)
Cord blood transplantations
Laughlin et al. [30] N = 68 49% NR 28% NR
Gluckman et al. [31] N = 108 NR 17% (CR2 or higher) NR NR
Long et al. [32] N = 57 50% 25%* 19% NR
Stevens et al. [33] N = 391 NR 30.2% NR 23%
Rocha et al. [34] N = 98 NR 40%* NR NR
Laughlin et al. [35] N = 150 45% NR 26% NR
Cornetta et al. [36] N = 34 47% 17% NR NR
Weighted average (SD) 47% (8.4%) 27.9% (6.3%) 24.7% (5.4%) 14.4% (4.4%)‡
*Information estimated from a graph.
†Estimates excludes 525 patients who received the transplantation in CR1.
‡Only one cord blood transplantation study provided 5-year survival [33], estimated at 23%, uncertainty exists around this one estimate reported only in abstract form. Since
the 5-year survival with BM/PBSC was estimated at 18.2% and since there is no reason to believe that cord blood transplantation would have a higher survival than BM/PBSC,
we have applied the rate of survival betweenYears 3 and 5 from BM/PBSC to cord blood (18.2%/31.3% = 0.581), resulting in a 14.4% (= 24.7% ¥ 0.581) 5-year survival for cord
blood transplantation.
BM/PBSC, bone marrow/peripheral blood stem cells; CR, complete remission; NMDP, National Marrow Donors Program; NR, not reported.
Table 3 Clinical parameters included in the Markov model (base-case and multivariate sensitivity analyses)
Variable
BM/PBSC transplantations Cord blood transplantations
Base-case
Multivariate
sensitivity analysis
Data (distribution)¶
Multivariate
sensitivity analysis
Base-case Data (distribution)¶
Age at transplantation* 48 years — 48 years —
Survival 100 days 62.4% — 47% —
Survival 1 year 47% 47% (5.7%) 27.9% 27.9% (6.3%)
Survival 3 years 31.3% — 24.7% —
Survival 5 years 18.2% — 14.4% —
Survival 10 years 17.7% — 14% —
Chronic GVHD† 54.5%
[34,35,37,38]
Year 1: 54.5%
(6.5%)
Year 3‡: 13.6%
(1.6%)
39.5%
[30,32,34–36]
Year 1: 39.5%
(6.1%)
Year 3‡: 9.9%
(1.5%)
Disease relapses† 21.8% [34,35] Year 1: 21.8%
(4.6%)
Year 3‡: 5.5%
(1.2)
13.7%
[30,34–36]
Year 1: 13.7%
(6.3%)
Year 3‡: 3.4%
(1.6%)
Infections§ Cumulative rates — Cumulative rates —
Year 1 20% [51] 20% [51]
Year 2 25% [51] 25% [51]
Year 4 30% [51] 30% [51]
Year 6 35% [51] 35% [51]
Nontransplantation group
Life-years 0.75 years 0.75 (0.5, 1.5)
*Based on the last 65 cases at our institution.
†Chronic GVHD and disease relapses assumed to occur in Year 1.
‡Because of possible underreporting we have assumed that in Year 3, 25% of the patients who had suffered chronic GVHD or disease relapses in the previous years would
experience another one of the same event.
§Late (>50 days) infection rates did not differ between unrelated BM/PBSC and cord blood transplantations in a study [52]. Therefore long-term rates were assumed equal,
probabilities estimated from a graph [51].
¶The beta distribution was used in the probabilistic sensitivity analysis for all probability variables. For the variable “life-years” in the nontransplantation group, the triangular
distribution was used.
BM/PBSC, bone marrow/peripheral blood stem cells; GVHD, graft-versus-host disease.
Cost-Effectiveness of Stem Cell Transplantations 251
Table 5 shows the results of the probabilistic sensi-
tivity analyses. The acceptability curve (Fig. 3) shows
that the ICER was below $25,000 in approximately
5% of the simulations with cord blood transplantation
and in 65% of the simulations in BM/PBSC transplan-
tations. The ICER was below $50,000 in almost all
BM/PBSC simulations and in 66% for cord blood
simulations.
Discussion
Previous studies have evaluated the cost and/or cost-
effectiveness of BM/PBSC [26,40–47], but ours is the
ﬁrst to employ an efﬁcacy measure derived from
a systematic review. Furthermore, previous cost-
effectiveness studies either compared bone marrow
with peripheral blood stem cell transplantations, allo-
geneic with autologous transplantations, or in patients
not refractory to chemotherapy [47]. Our study was
the ﬁrst to provide a long-term estimate of the cost-
Table 4 Cost variables used in the base-case and multivariate sensitivity analyses
Cost variables
Cord blood transplantations BM/PBSC transplantations
Base-case
(estimated costs, $)
Multivariate
sensitivity
analysis
Distribution range*
Base-case
(estimated costs, $)
Multivariate
sensitivity
analysis
Data (distribution)*
0–100 days 88,822 75,000–160,000 64,978 45,485–130,000
(80,407 + 8,415)† (56,563 + 8,415)†
Follow-up 606 (Year 1) 424–1,515 606 (Year 1) 424–1,515
202 (Year 2) 141–505 202 (Year 2) 141–505
Disease relapses 10,576 7,403–26,440 10,576 7,403–26,440
Infections [48] 3,447 2,413–8,618 3,447 2,413–8,618
Chronic GVHD 2,716 1,901–6,790 2,716 1,901–6,790
Nontransplantation group
Treatment costs 20,702 14,500–52,000
*All distributions were assumed to be triangular with a lower limit of -30%, and upper limit of +250%.
†In-hospital hospital costs plus costs from hospital discharge to 100 days.
More information on the calculation of costs can be found at http://www.mcgill.ca/tau.
BM/PBSC, bone marrow/peripheral blood stem cells; GVHD, graft-versus-host disease.
Table 5 Results of base-case and multivariate sensitivity
analyses
Base-case
(3% discounting)
Multivariate
sensitivity analysis
(95% CI*/link)
No transplantation
Cost ($) 20,702 20,702 (17,021, 46,804)
Life-years 0.75 0.75 (0.58, 1.36)
BM/PBSC (ICER
compared with no
transplantation)
Incremental cost ($) 49,693 49,693 (24,445, 101,400)
Incremental life-years 3.04 3.04 (2.09, 3.53)
ICER ($) 16,346 16,346 (8,695, 38,006)
Cord blood (ICER
compared with no
transplantation)
Incremental cost ($) 72,157 72,157 (50,560, 126,086)
Incremental life-years 2.10 2.10 (1.00, 2.71)
ICER ($) 34,360 34,360 (23,101, 89,417)
BM/PBSC, bone marrow/peripheral blood stem cells; CI, conﬁdence interval; ICER,
incremental cost-effectiveness ratio.
*95% CI calculated through probabilistic sensitivity analyses using 1000 Monte Carlo
simulations.
Figure 2 Univariate sensitivity analysis of the
incremental cost-effectiveness ratio (ICER) of
cord blood and bone marrow/peripheral blood
stem cells (BM/PBSC) transplantation com-
pared with no transplantation obtained by
varying the number of years of life in the non-
transplantation group (3% discounting). HSCT,
hematopoietic stem cell transplantation.
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effectiveness of stem cells transplantation compared
with no transplantation in adult patients with acute
leukemias not expected to be cured with chemotherapy
and showed a high mortality during the ﬁrst few years
after either cord blood or BM/PBSC transplantations.
Although initial transplantation costs were high, there
were substantial long-term health beneﬁts compared
with a nontransplant alternative leading to ICER
values commonly considered societally and ﬁnancially
acceptable. This is partially explained by our institu-
tional policy of reserving unrelated transplantations to
patients with a very poor prognosis with conventional
therapies.
Although dependent on model assumptions, our
results appear relatively robust to both univariate and
multivariate analyses despite a systematic tendency
on our behalf to favor the nontransplantation group.
Speciﬁcally we demonstrated that these technologies
appear relatively cost-effective even if hospital costs
were much higher, and if nontransplantation group
survival was markedly improved. Nevertheless, the
higher costs of cord blood transplantation accompa-
nied by the imprecision in long-term efﬁcacy out-
comes result in more uncertainty for this technology.
The absence of appropriate comparative data
between cord blood and BM/PBSC transplantations
precludes any comparison between the two sources of
stem cells.
Estimates of the costs of bone marrow transplanta-
tion excluding harvesting costs are problematic and
have varied widely (from $29,500 to $139,000)
[26,40–46]. Part of the disparity may be accounted for
by geographic and temporal differences in per diem
hospital costs, different patient populations, varying
practice patterns and outcomes. Nevertheless, our
local costs are close to previous Canadian estimates
[26,48]. Because one unit of cord blood contains insuf-
ﬁcient cells to transplant an average 70 kg adult
(2 ¥ 107 nucleated cells/kg), our model more realis-
tically used the costs for two units. Nevertheless,
although cord blood graft transplants using two units
have been successfully performed [49], it is unknown if
this may inﬂuence clinical outcomes.
A limitation of our study is the unavailability of
precise information for several model variables. For
example, studies did not always allow data extraction
that corresponded directly to our population. Never-
theless, several publications corroborate our estimate
of long-term survival in patients with advanced disease
[20,21,23,50]. Also we assumed that the results of
clinical studies using only one cord blood unit would
be reproduced using two units. Other limitations were
of our use of single center cost data. Finally, quality-
adjusted life-years were not calculated because of the
absence of estimates of relevant health preferences in
the literature. Despite the above limitations, we feel
that our systematic use of conservative model assump-
tions to penalize the transplantation arms increases the
strengths of our conclusions. Moreover, our use of
only recent studies to estimate the efﬁcacy of trans-
plantation did assure that the most contemporary and
therefore hopefully the most relevant results were
incorporated.
From the point of view of the health policy
decision-maker, it is also important to appreciate the
overall budget impact of this technology. For example,
if a hospital carries out approximately 60 allogeneic
stem cell transplantations per year, at an estimated cost
of approximately $57,000 per bone marrow trans-
plantation, and $81,000 per cord blood transplanta-
tion, these technologies would cost the institution $3
million to $5 million per year.
Our cost-effectiveness results would suggest that
BM/PBSC sources should be the ﬁrst option for unre-
lated donors if clinically indicated. Nevertheless, if a
suitable donor cannot be located in a timely fashion,
this analysis suggests that cord blood is a reasonable
cost-effective substitute. Given that cord blood trans-
plantation, especially in adults, has been introduced
relatively recently, it is possible that efﬁcacy will con-
tinue to improve as we advance on the learning curve
and any such improvement will further improve their
cost-effectiveness.
In conclusion, the cost per life-year gained with
stem cells transplantation from either cord blood or
bone marrow/peripheral blood appears to lie within a
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Figure 3 Acceptability curve showing the pro-
portion of simulations that fall below a speciﬁc
cost-effectiveness level. Cost-effectiveness was
deﬁned as the incremental cost/life-year gained
with stem cells transplantation compared with
no transplantation. BM/PBSC, bone marrow/
peripheral blood stem cells.
Cost-Effectiveness of Stem Cell Transplantations 253
frequently accepted range for new technologies.
Nevertheless, because of their high costs, the budget
impact of these technologies will be considerable and,
given an escalating demand, can be expected to signiﬁ-
cantly increase health costs in the coming years.
Source of ﬁnancial support: Dr James Brophy is a funded
scholar of Les Fonds de Recherche en Santé Québec (FRSQ).
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